BridgeBio Pharma Inc (NAS:BBIO)
$ 27.94 0.18 (0.65%) Market Cap: 5.23 Bil Enterprise Value: 6.44 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 48/100

BridgeBio Pharma Inc R&D Day Transcript

Oct 12, 2021 / 12:30PM GMT
Release Date Price: $46.64
Grace Rauh
BridgeBio Pharma, Inc. - VP of Communications

Good morning, and welcome to BridgeBio Second Annual Virtual R&D Day. My name is Grace Rauh. I'm the Vice President of Communications at BridgeBio, and I want to thank all of you for joining us for this event.

We have an incredible agenda ahead of us today. We're going to be hearing from Richard Scheller, our Chairman of R&D, who will provide some opening remarks about human genetics and the important role that it plays in drug discovery. Next up, our Founder and CEO, Neil Kumar, who is going to be talking about what he calls BridgeBio's endless summer. You'll also hear from Cameron Turtle, our Chief Strategy Officer, who is going to be sharing an overview of our cardiorenal work before we take a deep dive into our cardiorenal programs, starting with our progress on transthyretin amyloidosis, known as ATTR, which is an underdiagnosed, rapidly progressive and ultimately fatal disease.

In that session, we will be joined by Jonathan Fox, Chief Medical Officer of BridgeBio Cardiorenal, who is going to be setting the stage for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot